BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8441028)

  • 1. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole.
    Clerc J; Izembart M; Dagousset F; Jaïs JP; Heshmati HM; Chevalier A; Léger AF; Barritault L
    J Nucl Med; 1993 Mar; 34(3):387-93. PubMed ID: 8441028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine therapy and thyrostatic drugs and iodine.
    Moka D; Dietlein M; Schicha H
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
    Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
    Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
    Sanyal D; Mukhhopadhyay P; Pandit K; Chatterjee J; Raychaudhuri M; Mukherjee S; Chowdhury S
    J Indian Med Assoc; 2008 Jun; 106(6):360-1, 372. PubMed ID: 18839646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.
    Sabri O; Zimny M; Schulz G; Schreckenberger M; Reinartz P; Willmes K; Buell U
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1229-33. PubMed ID: 10199759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity.
    Clerc J; Dagousset F; Izembart M; Jais JP; Heshmati HM; Alcaïs A; Chevalier A; Léger AF; Barritault L
    J Nucl Med; 1995 Feb; 36(2):217-23. PubMed ID: 7830117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children.
    Nebesio TD; Siddiqui AR; Pescovitz OH; Eugster EA
    J Pediatr; 2002 Jul; 141(1):99-103. PubMed ID: 12091858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thyroid diseases in sub-Saharan Africa].
    Sidibé el H
    Sante; 2007; 17(1):33-9. PubMed ID: 17897900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of carbimazole following radioiodine therapy on radiation dose to the thyroid.
    Gimlette TM; Kocak R; Herbert RG; Squire CR
    Nuklearmedizin; 1981 Apr; 20(2):72-5. PubMed ID: 6165965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dosage 131-I therapy of thyrotoxicosis (diffuse goiters). A five-year follow-up study.
    Cevallos JL; Hagen GA; Maloof F; Chapman EM
    N Engl J Med; 1974 Jan; 290(3):141-3. PubMed ID: 4859623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.